Pharmacogenomics of rare and monogenic disorders

Methods in Pharmacology and Toxicology

Volumn , Issue , 2008, Pages 479-497

  Maher, Paul D ^a  

^a U S PUBLIC HEALTH SERVICE   (United States)

Author keywords

disease classification; DNA; gene therapy; genomics; human genome; orphan products monogenic; pharmacogenomics; rare disease; recombinant; sickle cell anemia; therapy

Indexed keywords

AGALSIDASE BETA; ALGLUCERASE; ALPHA 1 ANTITRYPSIN; ANAGRELIDE; ANTITHROMBIN III; BETAINE; BIOLOGICAL PRODUCT; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; CARNITINE; CHAPERONE; DORNASE ALFA; FELBAMATE; GALSULFASE; GAMMA1B INTERFERON; HEMATIN; HUMAN GROWTH HORMONE; IDURONATE 2 SULFATASE; IMIGLUCERASE; LAMOTRIGINE; LARONIDASE; MERCAPTAMINE; ORPHAN PRODUCT; PEGADEMASE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RECOMBINANT LUTEINIZING HORMONE; THROMBATE III; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE INTERMITTENT PORPHYRIA; ADENOSINE DEAMINASE DEFICIENCY; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANOVULATION; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CARNITINE DEFICIENCY; CHRONIC GRANULOMATOUS DISEASE; COPROPORPHYRIA; CYSTIC FIBROSIS; CYSTINOSIS; DISEASE CLASSIFICATION; DRUG APPROVAL; ENVIRONMENTAL FACTOR; FABRY DISEASE; GAUCHER DISEASE; GENE THERAPY; GENETIC DISORDER; GENOMICS; GLYCOGEN STORAGE DISEASE TYPE 2; HEMOPHILIA A; HEMOPHILIA B; HOMOCYSTINURIA; HUMAN; HUMAN GENOME; HUNTER SYNDROME; HURLER SYNDROME; LENNOX GASTAUT SYNDROME; MAROTEAUX LAMY SYNDROME; MONOGENIC DISORDER; OSTEOPOROSIS; PHARMACOGENOMICS; PORPHYRIA VARIEGATA; PRIORITY JOURNAL; RARE DISEASE; REVIEW; SHORT STATURE; THROMBOCYTHEMIA; VON WILLEBRAND DISEASE;

EID: 78649420247     PISSN: 15572153     EISSN: 19406053     Source Type: Book Series    
DOI: 10.1007/978-1-59745-439-1_21     Document Type: Review

References (68)

1. Mendel G (1866) Versuche über pflanzen-hybriden. Verh Naturforsch Ver Brünn 4:3-47 (in English (1901) J R Hortic Soc 26:1-32).
2. Avery OT, Mac Leod CM, McCarty M (1944) Studies on the chemical nature of the substance inducing transformation of pneumonococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med 79:137-158.
3. Watson JD, Crick FH (1953) Molecular structure of nucleic acids. Nature 171:737-738.
4. Bearn AG, Miller ED (1979) Archibald Garrod and the development of the concept of inborn errors of metabolism. Bull Hist Med 53(3):315-28.
5. Garrod A (1902) The incidence of alkaptonuria: a study in chemical individuality. Lancet 2:1616-1620
6. Berg J, Tymoczko J, Styrey L (2002) Biochemistry, Fifth Ed. http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=stryer.section.3259 (accessed March 17, 2008).
7. Pollak MR, Chou Y-HW, Cerda J J, Steinmann B, La Du BN, Seidman JG, Seidman CE (1993) Homozygosity mapping of the gene for alkaptonuria to chromosome 3q2. Nature Genet 5:201-204.
8. Adams MD, Dubnick M, Kerlavage AR, Moreno R, Kelley JM, Utterback TR, Nagle JW, Fields C, Venter JC (1992) Sequence identification of 2,375 human brain genes. Nature 355(6361):632-4.
9. National Center for Biotechnology Information. http://www.ncbi.nlm.nih. gov/About/primer/est.html (accessed May 19, 2007).
10. Venter JC, Adams MD, Myers EW et al (2001) The sequence of the human genome [published erratum appears in Science 2001 Jun 5;292(5523):1838]. Science 291(5507):1304-51.
11. Collins FS, Green ED, Guttmacher AE et al (2003) A vision for the future of genomics. Nature 422(6934):835-47.
12. Stein LD (2004) Human genome: end of the beginning. Nature 431:915-916.
13. Human Genome Project Information. http://www.ornl.gov/sci/techresources/ Human-Genome/medicine/assist.shtml (accessed March 17, 2008).
14. Nekrutenko A (2004) Reconciling the numbers: ESTs versus protein-coding genes. Mol Biol Evol 21(7):1278-1282.
15. Gaffney DJ, Keightley PD (2004) Unexpected conserved noncoding DNA blocks in mammals. Trends Genet 20(8):332-337.
16. Orphan Drug Act. (1982) Pub L. No. 97-414, 96 Stat. 2049.
17. Rados C (2003) Orphan products: hope for people with rare diseases. FDA consumer magazine. Nov-Dec 2003.
18. http://www.hapmap.org/ (accessed May 19, 2007).
19. Chiche JD, Cariou A, Mira JP (2002) Bench-to-bedside review: fulfilling the promises of the Human Genome Project. Crit Care 6(3):212-215.
20. http://www.gei.nih.gov/ (accessed May 14, 2007).
21. Scone EA, Khan TI, Wynne HA et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regime. Blood 106:2329-2333.
22. Abuchowski A. Severe combined immuonogenicity disease: enzyme therapy. OOPD, Rockville, MD. Grant no. FDR-000285-01. Available online at: http://www.fda.gov/orphan/grants/previous.htm. (accessed March 17, 2008).
23. Quoted in "Adopting orphan diseases: rare medical disorders repay researchers attention tenfold, with medical insights and useful drugs." Red Herring. January 22, 2001.
24. Brown MS, Goldstein JL (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232(4746):34-47.
25. Brown MS, Goldstein JL (1996) Heart attacks: gone with the century? Science 272: 629.
26. Breunig F, Weidemann F, Beer M et al (2003) Fabry disease: diagnosis and treatment. Kidney Int Suppl 63(84):S181-5.
27. Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, Bennett S, Brewster D, McMichael AJ, Greenwood BM (1991) Common West African HLA antigens are associated with protection from severe malaria. Nature 352:595-600.
28. Flint J, Harding RM, Boyce AJ, Clegg JB (1998) The population genetics of the haemoglobinopathies. Baillieres Clin Haematol 11:1-51.
29. Nagel RL, Fleming AF (1992) Genetic epidemiology of the betas gene. Baillieres Clin Haematol 5:331.
30. Kwiatkowski DP (2005) How malaria has affected the human genome and what human genetics can teach us about malaria. Am J Hum Genet 77(2):171-192.
31. Woo SLC (1989) Molecular basis and population genetics of phenylketonuria. Biochemistry 28:1-7
32. Woolf LI (1986) The heterozygote advantage in phenylketonuria. Am J Hum Genet 38(5):773-775.
33. Gabriel SE et al (1994) Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science 266(5182):107-9.
34. Spyropoulos B, Moens PB, Davidson J, Lowden JA (1981) Heterozygote advantage in Tay- Sachs carriers? Am J Human Genet 3:375-80.
35. Miller H, Mason SJ, Clyde DF, McGinniss MH (1976) The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 295(6):302-4.
36. Nowak R (2001) Disaster in the making. New Sci 169:4-5.
37. Christensen CD, Beaton S, Hall DF, Ramshaw IA (2001) Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 75(3):1205-1210.
38. Fueyo J, Alemany R, Gomez-Manzano C (2003) Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 95(9):652-60.
39. Menkes JH, Hurst PL, Craig JM (1954) A new syndrome: progressive familial infantile cerebral dysfunction associated with an unusual urinary substance. Pediatrics 14:462-467.
40. Westall RG, Dancis J, Miller S (1957) Maple syrup urine disease. Am J Dis Child 94: 571-572.
41. National Center for Biotechnology Information. Online Mendellian Inheritance in Man (OMIM) #248600: Maple syrup urine disease. http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=248600 (accessed March 17, 2008).
42. Stephenson J (2001) Antibiotics show promise as therapy for genetic disorders. JAMA 285:2067-8.
43. Bidoul L et al (2004) Premature stop codons involved in muscular dystrophies show a broad spectrum of read through efficiencies in response to gentamicin treatement. Gene Ther 11:619-27.
44. Wilschanski M, Yahav Y, Yaacov Y et al (2003) Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 349:1433-41.
45. Garman SC, Garboczi DN (2002) Minireview: structural basis of Fabry disease. Mol Genet Metab 77:3-11.
46. Helenius A, Marquardt T, Braakman I (1992) The endoplasmic reticulum as a protein folding compartment. Trends Cell Biol 2:227-31.
47. Fan JQ (2003) A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci 24:356-36.
48. Frustaci A, Chimenti C, Ricci R et al Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose infusion therapy. N Engl J Med 2001;345:25-32.
49. ibid., ref. 23.
50. Chaffee S, Hersfield MS (1990) Imuune response to polyethylene glycol modified bovine adenosine deaminase (PEG-ADA). Pediatr Res 27(4 Pt 2):155A.
51. Alter MJ, Kruszon-Moran D, Nainan OV et al (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341(8):556-62.
52. World Health Organization. Fact Sheet N164. http://www.who.int/ mediacentre/factsheets/fs164/en/ (accessed May17, 2007).
53. http://www.fda.gov/orphan/designat/list.htm (accessed May 15, 2007).
54. FDA News. FDA approves first treatment for pompe disease. P06-63. April 28, 2006. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01365.html (accessed May17, 2007).
55. ClinicalTrials.gov. Search field: Experimental Treatment; search field: Enzyme replacement (accessed March 17, 2008).
56. Neergaard L (2002) FDA OKs drug to fight liver disease. Associated Press: http://www.communities.ninemsn.com/tyrosinemia/ntbc.msnw.
57. Mehta A (2006) Clinical experience with substrate reduction therapy. Eur J Intern Med 17(Suppl):S13-5.
58. Aerts JM, Hollak CE, Boot RG, Groener JE, Maas M (2006) Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis 29(2-3):449-56.
59. Couzin J, Kaiser J (2005) Gene therapy: as Gelsinger case ends, gene therapy suffers another blow. Science 307(5712):1028.
60. Hacein-Bey-Abina S, von Kalle C, Schmidt M et al (2003) LMO2-associated clonal T proliferation in two patients after gene therapy for SCID-X. Science 302(5644):415-9.
61. ClinicalTrials.gov. Search field: Experimental Treatment; search field: Enzyme replacement (accessed March 17, 2008).
62. Kaiser J (2005) Putting the fingers on gene repair. Science 310(5756):1894-189.
63. Urnov FD, Miller JC, Lee Y-L et al (2005) Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435:646-651.
64. Safety and efficacy study of antisense oligonucleotides in Duchenne muscular dystrophy. ClinicalTrials.gov Identifier: NCT00159250 http://clinicaltrials.gov/ct/show/NCT00159250?order=2 (accessed May 19, 2007).
65. FDA Consumer Information (1998) Vitravene [package insert]. FDA, Rockville, MD.
66. U.S. Army Medical Research. Institute of Infectious Diseases (2006) Gene-specific ebola therapies protect nonhuman primates from lethal disease. Fort Detrick, MD. http://www.usamriid.army.mil/press%20releases/warfield-press- release.pdf (accessed March 17, 2008).
67. Gleave ME, Monia BP. (2005) Antisense therapy for cancer. Nat Rev Cancer 5:468-479.
68. Bantounas I, Phylactou LA, Uney JB (2004) RNA interference and the use of small RNA to study gene function in mammalian systems. J Mol Endocrinol 33:545-57.